bpc-157 safety human case reports evidence clinical trials and the Difference Between an Gap and a Cover-Up: What the entire evidence base actually looks like, and the questions to ask next. — WellFounded bpc-157 BPC-157 continues to be one

The mechanisms by which inflammation affects tight junction structure and function and transcellular mechanisms such as endocytosis are largely unknown, although reproducible correlations have been observed between the severity of experimental and clinical disease and on the one hand and transepithelial electrical resistance, transport of paracellular markers, and systemic LPS concentrations and on the other [42, 86]

Taking BPC-157 acetate orally means losing approximately 97% of the dose to gastric degradation

Product that was USP-compliant when it left the original manufacturer may no longer be compliant after repackaging, and the repackager typically does not perform the release testing that would detect the degradation

In the end, the controversy about particle size is not much of a controversy